Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 163Carcinoma, Renal Cell 45Urinary Bladder Neoplasms 33Carcinoma, Transitional Cell 19Lung Neoplasms 14Melanoma 11Neoplasm Metastasis 10Glioma 10Breast Neoplasms 9Wilms Tumor 8Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Sarcoma 7Kidney Neoplasms 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Ureteral Neoplasms 6Testicular Neoplasms 6Rhabdoid Tumor 6Pancreatic Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Brain Neoplasms 6

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Magnetic Resonance Spectroscopy × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡